1. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). Issue 2 (6th February 2019) Authors: Geven, Christopher; Blet, Alice; Kox, Matthijs; Hartmann, Oliver; Scigalla, Paul; Zimmermann, Jens; Marx, Gernot; Laterre, Pierre-François; Mebazaa, Alexandre; Pickkers, Peter Journal: BMJ open Issue: Volume 9:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). Issue 2 (6th February 2019) Authors: Geven, Christopher; Blet, Alice; Kox, Matthijs; Hartmann, Oliver; Scigalla, Paul; Zimmermann, Jens; Marx, Gernot; Laterre, Pierre-François; Mebazaa, Alexandre; Pickkers, Peter Journal: BMJ open Issue: Volume 9:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Addition of copeptin improves diagnostic performance of point-of-care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction — A pilot study. (1st November 2015) Authors: Vafaie, Mehrshad; Biener, Moritz; Mueller, Matthias; Abu Sharar, Haitham; Hartmann, Oliver; Hertel, Sabine; Katus, Hugo A.; Giannitsis, Evangelos Journal: International journal of cardiology Issue: Volume 198(2015) Page Start: 26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bioactive adrenomedullin for assessment of venous congestion in heart failure. (28th July 2022) Authors: Egerstedt, Anna; Czuba, Tomasz; Bronton, Kevin; Lejonberg, Carl; Ruge, Thoralph; Wessman, Torgny; Rådegran, Göran; Schulte, Janin; Hartmann, Oliver; Melander, Olle; Smith, J. Gustav Journal: ESC heart failure Issue: Volume 9:Number 5(2022) Page Start: 3543 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bioactive Adrenomedullin, Organ Support Therapies, and Survival in the Critically Ill: Results from the French and European Outcome Registry in ICU Study. Issue 1 (January 2020) Authors: Lemasle, Léa; Blet, Alice; Geven, Christopher; Cherifa, Ményssa; Deniau, Benjamin; Hollinger, Alexa; Fournier, Marie-Céline; Monnet, Xavier; Rennuit, Isabelle; Darmon, Michael; Laterre, Pierre-François; Struck, Joachim; Hartmann, Oliver; Bergmann, Andreas; Mebazaa, Alexandre; Gayat, Etienne Journal: Critical care medicine Issue: Volume 48:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Bioactive adrenomedullin, proenkephalin A and clinical outcomes in an acute heart failure setting. Issue 2 (3rd July 2019) Authors: Molvin, John; Jujic, Amra; Navarin, Silvia; Melander, Olle; Zoccoli, Giada; Hartmann, Oliver; Bergmann, Andreas; Struck, Joachim; Bachus, Erasmus; Di Somma, Salvatore; Magnusson, Martin Journal: Open heart Issue: Volume 6:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. (31st August 2019) Authors: Takagi, Koji; Blet, Alice; Levy, Bruno; Deniau, Benjamin; Azibani, Feriel; Feliot, Elodie; Bergmann, Andreas; Santos, Karine; Hartmann, Oliver; Gayat, Etienne; Mebazaa, Alexandre; Kimmoun, Antoine Journal: European journal of heart failure Issue: Volume 22:Number 2(2020) Page Start: 279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study. Issue 1 (9th January 2023) Authors: van Lier, Dirk; Deniau, Benjamin; Santos, Karine; Hartmann, Oliver; Dudoignon, Emmanuel; Depret, François; Plaud, Benoit; Laterre, Pierre-Francois; Mebazaa, Alexandre; Pickkers, Peter Journal: ERJ open research Issue: Volume 9:Issue 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. (31st August 2019) Authors: Deniau, Benjamin; Rehfeld, Linda; Santos, Karine; Dienelt, Anke; Azibani, Feriel; Sadoune, Malha; Kounde, Paul R.; Samuel, Jane L.; Tolpannen, Heli; Lassus, Johan; Harjola, Veli‐Pekka; Vodovar, Nicolas; Bergmann, Andreas; Hartmann, Oliver; Mebazaa, Alexandre; Blet, Alice Journal: European journal of heart failure Issue: Volume 22:Number 2(2020) Page Start: 290 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock. (1st September 2018) Authors: Caironi, Pietro; Latini, Roberto; Struck, Joachim; Hartmann, Oliver; Bergmann, Andreas; Bellato, Valentina; Ferraris, Sandra; Tognoni, Gianni; Pesenti, Antonio; Gattinoni, Luciano; Masson, Serge Journal: Clinical chemistry Issue: Volume 64:Number 9(2018) Page Start: 1361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗